<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11161372</article-id><article-id pub-id-type="pmc">2363708</article-id><article-id pub-id-type="pii">6691572</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1572</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vasey</surname><given-names>P A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Atkinson</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Coleman</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Crawford</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cruickshank</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Eggleton</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fleming</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Parkin</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reed</surname><given-names>N S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kaye</surname><given-names>S B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab>on behalf of the Scottish Gynaecological Cancer Trials Group</collab></contrib></contrib-group><aff id="aff1"><label>1</label>CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT</aff><aff id="aff2"><label>2</label>Belfast City Hospital, Belfast BT9 7AB, Belfast</aff><aff id="aff3"><label>3</label>YCR Cancer Research Centre, Weston Park Hospital, Sheffield, S10 2SJ</aff><aff id="aff4"><label>4</label>Airedale General Hospital, Steeton, West Yorkshire, BD20 6TD</aff><aff id="aff5"><label>5</label>Aberdeen Royal Infirmary, Aberdeen, AB9 2ZB</aff><aff id="aff6"><label>6</label>Rhone-Poulenc (now Aventis Pharma), Anthony, France</aff><aff id="aff7"><label>7</label>Bristol Oncology Centre, Bristol, BS2 8ED</aff><author-notes><fn fn-type="present-address" id="note1"><p>Merck KGaA, Darmstadt, Germany</p></fn></author-notes><pub-date pub-type="ppub"><month>01</month><year>2001</year></pub-date><volume>84</volume><issue>2</issue><fpage>170</fpage><lpage>178</lpage><history><date date-type="received"><day>08</day><month>06</month><year>2000</year></date><date date-type="rev-recd"><day>21</day><month>09</month><year>2000</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic&#x02013;IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28&#x02013;85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m<sup>2</sup>); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79&#x00025;) completed 6 cycles; 17 (12&#x00025;) stopped due to toxicity. 104 patients (75&#x00025;) had CTC grade IV neutropenia, and 5 patients (4&#x00025;) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6&#x00025;) experienced grade II&#x02013;III neurotoxicity (all sensory; no motor &#x0003e; grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66&#x00025; (49/74); CA125 response was 75&#x00025; (70/93). Median progression-free survival was 16.6 months (95&#x00025; CI 13.3&#x02013;19.1). Recommended doses are carboplatin AUC 5 (via<sup>51</sup> Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m<sup>2</sup>. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>ovarian carcinoma</kwd><kwd>chemotherapy</kwd><kwd>docetaxel</kwd><kwd>carboplatin</kwd></kwd-group></article-meta></front></article>


